Brought to you by 
Cor and Schering sign $120mm Integrilin deal; restructured
08 May 2015
Executive Summary
Cor Therapeutics (cardiovascular therapeutics) and Schering-Plough will co-develop and market Cor's Phase III platelet aggregation inhibitor Integrilin, in a deal that could be worth over $120 million to Cor.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cor and Schering sign $120mm Integrilin deal; restructured
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice